Bryan Vaughn Sells 234 Shares of Labcorp (NYSE:LH) Stock

Labcorp Holdings Inc. (NYSE:LH) EVP Bryan Vaughn sold 234 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the transaction, the executive vice president owned 6,746 shares of the company’s stock, valued at $1,930,637.74. The trade was a 3.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Labcorp Trading Down 0.1%

Shares of NYSE:LH opened at $284.07 on Wednesday. The company’s 50-day moving average price is $263.04 and its two-hundred day moving average price is $266.65. Labcorp Holdings Inc. has a one year low of $241.81 and a one year high of $293.72. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54. The stock has a market capitalization of $23.29 billion, a PE ratio of 25.16, a price-to-earnings-growth ratio of 1.99 and a beta of 0.89.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter last year, the company earned $3.84 EPS. Labcorp’s revenue for the quarter was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, equities analysts forecast that Labcorp Holdings Inc. will post 18 EPS for the current fiscal year.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Friday, May 29th were paid a dividend of $0.72 per share. The ex-dividend date was Friday, May 29th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. Labcorp’s dividend payout ratio is currently 25.51%.

Analyst Ratings Changes

Several research firms recently weighed in on LH. Robert W. Baird set a $334.00 target price on shares of Labcorp in a research note on Friday, May 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Evercore reissued an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. Finally, Wall Street Zen cut shares of Labcorp from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $308.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Brighton Jones LLC bought a new position in Labcorp during the fourth quarter worth $991,000. Integrated Wealth Concepts LLC raised its position in shares of Labcorp by 7.9% in the first quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company’s stock valued at $565,000 after purchasing an additional 177 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Labcorp by 52.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company’s stock worth $82,353,000 after buying an additional 121,304 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Labcorp during the 2nd quarter worth about $5,873,000. Finally, First Trust Advisors LP boosted its holdings in shares of Labcorp by 83.2% during the 2nd quarter. First Trust Advisors LP now owns 86,046 shares of the medical research company’s stock worth $22,588,000 after buying an additional 39,087 shares during the period. 95.94% of the stock is owned by institutional investors and hedge funds.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.